Insight

Jul 29, 2024, 13:24

Gautam Mehta et al. summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki – FDA Oncology

FDA Oncology shared a post on X about a paper titled “FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations” published in The Oncologist Journal.

Authors: Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh.

Gautam Mehta et al. summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki - FDA Oncology

“OCE’s Gautam Mehta and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer – via The Oncologist Journal.”

Source: FDA Oncology/X

Anup K Amatya cancer Claudia P Miller fam-trastuzumab deruxtecan-nxki FDA Approval Summary FDA Oncology Gautam Mehta Harpreet Singh Jeanne F Zirkelbach Jiang Liu Julia A Beaver Lili Pan Marc Theoret Mirat Shah Nam Atiqur Rahman non small cell lung cancer OCE OncoDaily Oncology Pallavi S Mishra-Kalyani Paul Kluetz Paz J Vellanki Richard Pazdur Stephanie L Aungst The Oncologist Journal Yi Ren Yuzhuo Pan

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage